Optimizing drug therapy in frail patients with type 2 diabetes mellitus.
Nuria Molist-BrunetD Sevilla-SánchezE Puigoriol-JuvantenyJ González-BuenoN Solà-BonadaM Cruz-GrullónJ Espaulella-PanicotPublished in: Aging clinical and experimental research (2019)
There is a high prevalence of T2DM in the elderly. As the frailty of patients increases, so does the prevalence of IP. The application of PCP model enables drug therapy optimization in frail patients according to their main therapeutic goal, and contributes to provide clinical evidences on the applicability of a set of knowledge areas from the theoretical framework to the daily clinical practice.